About: Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.60 (-1.16%)
RNTX NASDAQ Rein Therapeutics Inc
Rein Therapeutics Inc share price
Atividade de preço de RNTX
Último preço
$ 0,600
Variação (24h)
-0,01 USD (1,16%)
Volume
97.45K
Volume (média 4 sem.)
-
Abertura
$ 0,60
Variação do dia
$ 0,58 - $ 0,61
Fechamento anterior
$ 0,60
Último negócio
23 Oct, 3:26 pm GMT+0
Atrasado
23 Oct, 3:26 pm GMT+0
RNTX price performance
Atrasado
23 Oct, 3:26 pm GMT+0
quote.marketSignals